{"_buckets": {"deposit": "2933f43d-fdb2-460b-add8-f8fcc262c207"}, "_deposit": {"id": "3789", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3789"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003789", "sets": ["461:462"]}, "author_link": ["7049", "7050", "7051", "7052", "7053"], "item_1628147817048": {"attribute_name": "\u51fa\u7248\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2009-03-15", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-2", "bibliographicPageEnd": "111", "bibliographicPageStart": "107", "bibliographicVolumeNumber": "278", "bibliographic_titles": [{"bibliographic_title": "JOURNAL OF THE NEUROLOGICAL SCIENCES"}]}]}, "item_6_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "The clinical effect of the GABAergic drug gabapentin was evaluated in 11 patients with spinocerebellar ataxia type 6 (SCA6). The total period of gabapentin treatment was 4 weeks, and outcome measures were determined with the International Cooperative Ataxia Rating Scales (ICARS) and postural sway studies. At week 4, 5 patients showed a decrease of the ICARS values by more than 10% compared with the pretreatment baseline. Eight patients showed a more than 10% decrease of the sway area (SA) and/or sway path length (SPL) values in postural sway Studies. The ICARS values and SA/SPL values were not necessarily consistent in each patient, but 3 patients showed a more than 10% decrease in the ICRAS, SA, and SPL values at week 4 when compared to the pre-treatment baseline. As a whole, the efficacy of gabapentin was not statistically confirmed in the 4-week trial because of the variation in efficacy in each patient, but the data are indicative that some SCA6 patients could benefit from gabapentin treatment.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "JOURNAL OF THE NEUROLOGICAL SCIENCES. 278(1-2):107-111 (2009)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "Yoshida, Kunihiro", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.yhfNHFkh.html"}, {"subitem_link_text": "Morita, Hiroshi", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.HUyNHhkh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000263692300021"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "ELSEVIER SCIENCE BV"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "19157422"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/19157422", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1016/j.jns.2008.12.017"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.jns.2008.12.017", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "Copyright\u00a9 2008 Elsevier B.V."}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0022-510X", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0022-510X", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00703265", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Spinocerebellar ataxia type 6 (SCA6); Gabapentin; The International Cooperative Ataxia Rating Scales (ICARS); Voltage-dependent calcium channel (VDCC); gamma-aminobutyric acid (GABA); Postural sway study"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "ALPHA(1A)-VOLTAGE-DEPENDENT CALCIUM-CHANNEL; CORTICAL CEREBELLAR ATROPHY; GATED CA2+ CHANNELS; RATING-SCALE; PREGABALIN; SUBUNITS; PATIENT; BENEFIT; TREMOR; TARGET"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "The clinical effect of the GABAergic drug gabapentin was evaluated in 11 patients with spinocerebellar ataxia type 6 (SCA6). The total period of gabapentin treatment was 4 weeks, and outcome measures were determined with the International Cooperative Ataxia Rating Scales (ICARS) and postural sway studies. At week 4, 5 patients showed a decrease of the ICARS values by more than 10% compared with the pretreatment baseline. Eight patients showed a more than 10% decrease of the sway area (SA) and/or sway path length (SPL) values in postural sway Studies. The ICARS values and SA/SPL values were not necessarily consistent in each patient, but 3 patients showed a more than 10% decrease in the ICRAS, SA, and SPL values at week 4 when compared to the pre-treatment baseline. As a whole, the efficacy of gabapentin was not statistically confirmed in the 4-week trial because of the variation in efficacy in each patient, but the data are indicative that some SCA6 patients could benefit from gabapentin treatment. (c) 2008 Elsevier B.V. All rights reserved."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura,  Katsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7049", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida,  Kunihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7050", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki,  Daigo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7051", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morita,  Hiroshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7052", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda,  Shu-ichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7053", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Spinocerebellar_ataxia_type_6_SCA6.pdf", "filesize": [{"value": "315.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 315200.0, "url": {"label": "Spinocerebellar_ataxia_type_6_SCA6.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3789/files/Spinocerebellar_ataxia_type_6_SCA6.pdf"}, "version_id": "a5de6efe-2f71-4bd5-9d2a-ba43b9ef23c5"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Spinocerebellar ataxia type 6 (SCA6)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Gabapentin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "The International Cooperative Ataxia Rating Scales (ICARS)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Voltage-dependent calcium channel (VDCC)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gamma-aminobutyric acid (GABA)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Postural sway study", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/16902", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2013-04-01"}, "publish_date": "2013-04-01", "publish_status": "0", "recid": "3789", "relation": {}, "relation_version_is_last": true, "title": ["Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin"], "weko_shared_id": -1}